COLLEGEVILLE, PennLovenox (enoxaparin sodium) Injection, from
Rhône-Poulenc Rorer Inc., has received FDA approval for the
inpatient treatment of acute deep-vein thrombosis (DVT) with or
without pulmonary embolism and the outpatient treatment of acute DVT
without pulmonary embolism. Both indications require that Lovenox be
administered in conjunction with warfarin sodium.
Cancer surgery and chemotherapy are risk factors for DVT, the company
said. Until now, the standard treatment has been unfractionated
heparin, administered through continuous IV infusion and requiring
hospitalization for several days.
Now, the company said, patients diagnosed with DVT can be treated in
the hospital or in their own homes via twice-daily subcutaneous
injections of Lovenox. A study at Kaiser Permanente Medical Center,
Fontana, Calif, showed an estimated cost savings of $547 per patient
with home use of Lovenox.
Lovenox, a low-molecular-weight heparin, was initially approved in
1993 for prevention of DVT in hip and knee replacement surgery and
high-risk abdominal surgery.